 |
ShanghaiMay 14, 2026 /PRNewswire/ — Kejun Pharmaceuticals announced the completion of a Series C financing round exceeding RMB 300 million in the first quarter of 2026. This round was led by Walvax Biotechnology, with continued support from existing shareholder Tailong Capital’s Taikun Fund, and introduced several renowned investment institutions including Qianhai Fangzhou and Shenzhen Guarantee Venture Capital. The funds raised will primarily be used to accelerate the global clinical development of multiple core and key pipeline assets. The combined backing from industrial capital and professional institutions marks the company’s entry into a new fast track of growth.
Since its establishment in Zhangjiang, Shanghai in 2018, Kejun Pharmaceuticals has built globally leading “Aosheng” mRNA technology platform and “Puyu” prodrug technology platform, focusing on the research and development of innovative drugs with global competitiveness. The pipeline includes multiple innovative drugs with global independent intellectual property rights and significant market potential. The company’s core team members all come from world-renowned multinational pharmaceutical companies, possessing extensive experience in innovative drug R&D, clinical operations, and industrialization in multiple fields such as cardiovascular and cerebrovascular diseases, metabolism, and antivirals.
Figure: Kejun’s Current Pipeline Progress
The company’s core product, Efogrel (CG-0255), is a first-in-class, next-generation P2Y12 receptor inhibitor available in both intravenous and oral formulations. Utilizing an innovative thiol-hydrolyzing prodrug design, it achieves rapid onset of action (injection <15 minutes, oral <30 minutes) and completely overcomes the "clopidogrel resistance" issue present in approximately 58% of the Chinese population. Clinical data show superior antiplatelet efficacy, with a 2mg dose achieving equivalent efficacy to 300mg of clopidogrel, along with good safety, low individual variability, and low risk of drug-drug interactions. Its injectable formulation can fill a global gap in stroke treatment, while the oral formulation effectively addresses existing clinical treatment pain points. Currently, this product is advancing registration clinical studies in the United States and concurrently conducting Phase II clinical studies in China.
In addition to the core product, multiple innovative drug pipelines with global independent intellectual property rights at Kejun Pharmaceuticals have also achieved significant progress:
CG-0416 (Weight Loss and Metabolic Liver Disease): A next-generation, highly selective liver-targeted THR-β agonist has successfully entered Phase I clinical stage. This is another liver-targeted innovative drug developed based on the “Puyu” targeted prodrug technology platform. Its differentiated advantage lies in not relying on central appetite suppression, effectively reducing liver fat and body weight while significantly minimizing muscle loss, potentially offering a new all-oral option for “high-quality weight loss” for patients with obesity and metabolic diseases.
CG-1999 (Functional Cure for Hepatitis B): The company has developed a therapeutic vaccine aimed at achieving a functional cure for hepatitis B using its “Aosheng” mRNA technology platform. It effectively induces specific immune responses, thereby achieving effective suppression and clearance of the hepatitis B virus. In animal models, the combination of CG-1999 with siRNA/ASO produces a clear synergistic effect, significantly accelerating the reduction of hepatitis B virus surface antigen HBsAg while effectively suppressing viral rebound after siRNA/ASO withdrawal.
Based on solid technological strength, Kejun Pharmaceuticals will continue to intensify original innovation. Leveraging the funds from this financing round to accelerate the clinical development of core products and key pipelines, the company will also persistently drive the iterative upgrades of its two core technology platforms. It plans to further advance the Investigational New Drug (IND) application preparations for several highly promising preclinical candidate compounds (PCCs), accelerating the entry of more high-quality, globally competitive innovative drugs into clinical use to benefit patients both domestically and internationally.
Dr. Hexin Gong, Founder and CEO of Kejun Pharmaceuticals, stated: “We sincerely thank both new and existing investors for their recognition and support. This financing round is a significant milestone for the company’s development and will greatly assist us in accelerating the global clinical development of our core products. Kejun Pharmaceuticals is always committed to addressing major clinical needs in cardiovascular and cerebrovascular diseases, metabolic disorders, and more through original innovation, bringing better treatment options to patients worldwide as soon as possible.”